A Major Unmet Need in a Rapidly Growing Market
The global female infertility market exceeds USD 39B and is projected to grow beyond USD 85B by 2034. Despite major advances in embryo selection and laboratory techniques, IVF success rates remain capped at approximately 35%, leaving many patients without effective options.
Increasing evidence indicates that the uterine environment — rather than embryo quality — is now the primary limiting factor in implantation success. Impaired lymphatic function within the endometrium disrupts immune balance and tissue stability, preventing reliable embryo attachment. Current IVF add-ons do not address this underlying biological constraint.
Our Solution (Vessely™)
Restoring Implantation Capacity, Not Just Optimising Embryos
Vessely™ is a prescription-based, locally administered lymphangiogenic therapy designed for integration into standard IVF workflows. By targeting the uterine microenvironment, it aims to restore endometrial readiness for implantation without systemic hormonal intervention.
Vessely™ focuses on regenerating the endometrium itself — representing a fundamentally different approach to improving IVF outcomes.
Unlocking the Endometrium’s Lymphatic Network
Vessely™ regenerates functional lymphatic vessels within the endometrium, helping restore immune regulation, fluid balance, and tissue stability during implantation. By re-establishing these biological conditions, the therapy supports a receptive uterine environment capable of sustaining early pregnancy.
✦ Regenerates lymphatic vessels
✦ Normalizes immune signalling
✦ Stabilizes implantation environment
Robust and Reproducible Restoration of Implantation
Preclinical studies using a severe infertility model demonstrated consistent restoration of implantation following targeted lymphatic regeneration. One-sided infertility experiments confirmed localized biological effect, with successful implantation observed only in treated tissue. Results were reproducible across multiple animals, supporting a causal relationship between lymphatic repair and fertility outcomes.
Severe Infertility Model (IUA)
Validated large-animal model representing profound implantation failure.
One-Sided Infertility
Implantation restored exclusively in treated uterine tissue, demonstrating localized biological effect.
Reproducibility
Consistent outcomes observed across multiple animals and study repeats.
Demonstrates biological causality — not correlation.
A Direct Translational Bridge to Human Infertility
Large-animal studies provide a clinically relevant model for dose optimization, manufacturing refinement, and trial design. The physiological similarity and uterine scale allow data to translate directly into human fertility applications while maintaining ethical, non-lethal research practices. This approach reduces development risk and supports a clear pathway toward First-in-Human evaluation.